Early Access — free while we kick the tires
EdgarHawk

STEINMAN LAWRENCE

Director

Director
1 filing analyzed · 1 company · Latest 2025-12-01

Never miss a filing from STEINMAN LAWRENCE

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Pasithea Therapeutics Corp. KTTA 1 0 Net buying

Activity

December 2025
high
Buy
133,333 shares
$100,000
Significance 8/10

Director STEINMAN LAWRENCE purchases 133,333 shares of KTTA at $0.75 (+200.9% vs prior holdings); cross-ticker track record shows 100% 90d win rate.

Director STEINMAN LAWRENCE purchased 133,333 shares at $0.75, more than doubling his holdings from 66,358 to 199,691 shares. His cross-ticker track record reveals exceptionally strong prior performance: an average 90-day return of +3068.6% with a 100% win rate across 3 prior buys, and at KTTA specifically, a prior 2023 buy returned +2709.7% over 90 days—both clearly well-timed entries. The current stock price of $1.16 is -63.2% from its 52-week high of $3.15, suggesting a depressed entry point relative to recent ranges. A cluster pattern shows 2 other insiders also bought within 14 days, indicating coordinated board-level accumulation. However, the company's fundamentals reveal structural challenges: unprofitable with a negative full-year net income of $-3,037,420.00 against only $218,608.00 in latest quarterly revenue, though annual revenue growth of +3130.4% suggests an early-stage trajectory. The tension between strong insider track record and negative profitability metrics warrants scrutiny of whether this reflects a high-conviction accumulation at a trough or execution risk in a loss-making operation.

Related insiders